Sedation during noninvasive mechanical ventilation with dexmedetomidine or midazolam: A randomized, double-blind, prospective study  by Senoglu, Nimet et al.
Current Therapeutic Research
Volume 71, Number 3, June 2010
 141
Accepted for publication April 7, 2010.  doi:10.1016/j.curtheres.2010.06.003
© 2010 Excerpta Medica Inc. All rights reserved. 0011-393X/$ - see front matter
Sedation During Noninvasive Mechanical Ventilation 
With Dexmedetomidine or Midazolam: A Randomized, 
Double-Blind, Prospective Study 
Nimet Senoglu, MD1; Hafize Oksuz, MD1; Zafer Dogan, MD1; Huseyin Yildiz, MD1; 
Hilmi Demirkiran, MD1; and Hasan Ekerbicer, MD2
1Kahramanmaras Sutcu Imam University, Department of Anaesthesiology and Reanimation, 
Kahramanmaras, Turkey; and 2Public Health Care Medicine Faculty of Medicine,  
Kahramanmaras, Turkey
ABSTRACT
Background: Effective noninvasive mechanical ventilation (NIV) requires a 
patient to be comfortable and in synch with the ventilator, for which sedation is usually 
needed. Choice of the proper drug for sedation can lead to improved clinical outcomes. 
Objective: The aim of this study was to compare the effectiveness of dexmed- 
etomidine and midazolam on sedation and their effects on hemodynamics and gas 
exchange. 
Methods: In this randomized, double-blind study, intensive care unit patients 
with acute respiratory failure due to acute exacerbations of chronic obstructive pulmo-
nary disease undergoing NIV were equally randomized to receive a loading dose of 
1 μg/kg IV dexmedetomidine or 0.05 mg/kg midazolam over 10 minutes followed 
by a maintenance infusion of 0.5 μg/kg/h dexmedetomidine (group D) or 0.1 mg/kg/h 
midazolam (group M). The following parameters were measured by a blinded clinician 
at baseline and 1, 2, 4, 6, 8, 12, and 24 hours after the loading dose was administered: 
Ramsay Sedation Score (RSS), Riker Sedation-Agitation Scale (RSAS), Bispectral Index 
(BIS), arterial blood gases, and vital signs. A second blinded investigator determined 
dosing changes according to the outcome of maintaining a target sedation level of 
RSS 2 to 3, RSAS 3 to 4, and BIS >85.
Results: A total of 45 patients were assessed for enrollment in the study; 4 did 
not meet the inclusion criteria and 1 refused to participate (men/women 19/21; mean 
age 58/60; all patients were receiving bronchodilators, steroids, antibiotics, and mu-
colytics). In both groups (n = 20), RSS significantly increased and RSAS levels and 
BIS values significantly decreased after the loading dose, compared with baseline (P < 
0.05). RSS levels were significantly lower beginning at 4 hours in group D compared 
with group M (P < 0.05). RSAS levels were not significantly different between the 
2 groups in the first 8 hours. However, RSAS levels were significantly higher at 8 hours 
after the loading dose was administered in group D compared with group M (P < 0.01). 
BIS was significantly higher in group D throughout the study period (P < 0.05). 
Respiratory rates and gas exchange values were not significantly different between the 
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2 groups. The number of times a change in infusion dose was needed was significantly 
lower in group D (2 patients with 1 change each) than in group M (3 patients with 
1 change, 1 patient with 2 changes, and 3 patients with 3 changes each) (P < 0.01). 
Conclusions: Dexmedetomidine and midazolam are both effective sedatives 
for patients with NIV. Dexmedetomidine required fewer adjustments in dosing com-
pared with midazolam to maintain adequate sedation. (Curr Ther Res Clin Exp. 2010; 
71:141–153) © 2010 Excerpta Medica Inc.
Key words: bispectral index, midazolam, dexmedetomidine, sedation, mechanical 
ventilation.
INTRODUCTION
In recent years, noninvasive mechanical ventilation (NIV) has become widely prac-
ticed in intensive care units (ICUs), primarily because its use can obviate the need for 
endotracheal intubation in patients with acute respiratory failure secondary to chronic 
obstructive pulmonary disease (COPD) or acute cardiogenic pulmonary edema.1,2 
NIV is commonly implemented in acute respiratory failure with refractory hypoxemia 
and/or immunocompromise, and during the postextubation period. Tolerance by the 
patient is an important factor to ensure success of NIV; therefore, methods to increase 
tolerance can lead to improved clinical outcomes.3 The methods and efficacy of NIV 
have been assessed in several prospective clinical trials, and a number of systematic 
reviews of sedation in the ICU setting have been published.1–7 A search of MEDLINE, 
SCOPUS, and EMBASE for English language articles using the terms noninvasive, 
ventilation, and sedation from inception through 2009 found that there have been no 
reported systematic studies on sedation during NIV. Only 3 published studies have re-
ported on sedation during NIV to date: 1 report on a web-based survey of practices and 
attitudes; 1 preliminary study of a single agent (dexmedetomidine); and a study that re-
ported 2 cases in which dexmedetomidine facilitated the induction of NIV.8–10
Many uncomfortable aspects of NIV, such as anxiety, panic, and difficulty synchro-
nizing with the ventilator, are treated with sedative–hypnotic medications (eg, mid-
azolam, propofol, opiates).11,12 Sedation facilitates mechanical ventilation, allays anxiety, 
encourages sleep, and modulates physiologic responses to stress such as tachycardia 
and hypertension.13 The sedation and analgesic regimens that physicians prefer to use 
during NIV are quite varied and, in some cases, inconsistent with the pharmacologic 
attributes of the medication and factors stated by patients to influence sedation 
choice.8 Benzodiazepines (33%) and opiates (29%) are reported to be the most often 
selected sedative agents for NIV.8 
Sedative agents should not depress respiration or hypoxic drive.3 Dexmedetomi-
dine is a centrally acting α2-adrenergic agonist that has been found to produce signif-
icant sedation without clinically relevant adverse effects (AEs) on respiration; as such, 
it has been used to facilitate weaning from mechanical ventilation.14–16
The most studied application of NIV is for treatment of acute exacerbations of 
COPD.17  In the clinical study by Plant et al,18  in which 236 patients with acute exac-
erbations of COPD were treated with NIV or standard therapy, intubation and mor-
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tality rates were significantly lower in the NIV group compared with standard therapy 
(15% vs 27% and 10% vs 20%, respectively). They also found more rapid improve-
ments in partial pressure of hydrogen in arterial blood, respiratory rate, and breath-
lessness in the NIV group.
Although the effectiveness of NIV during respiratory failure has been investigated 
in clinical studies, few studies have focused on the sedative agents used. A single-
agent study by Akada et al9 assessed the effects of dexmedetomidine for NIV. They 
found dexmedetomidine to be an efficacious sedative for patients undergoing NIV, 
but no control or comparison group was included. Takasaki et al10 reported 2 cases in 
which dexmedetomidine facilitated the induction of NIV for the treatment of acute 
respiratory failure caused by severe asthma without inducing respiratory depression. 
In a web-based survey of practices and attitudes by Devlin et al,8 the researchers 
sought to characterize current practices and attitudes regarding sedation during NIV. 
In their study of 2985 physicians, 790 (27%) responded, with the response rate being 
42% among Europeans and 19% among North Americans. Overall, benzodiaz-
epines alone (33%) or opioids alone (29%) were most frequently chosen as the seda-
tion regimen of choice. Lorazepam alone (18%) was next in frequency of use, followed 
by midazolam (15%), morphine (12%), and fentanyl (8%). Propofol-containing regi-
mens (7%) and dexmedetomidine-containing regimens (5%) were rarely chosen as 
first-line treatment. They concluded that few data exist regarding current sedation 
practices during NIV and practices vary widely within and between specialties and 
geographic regions.
Assessing and describing the level of sedation in a critically ill patient can be dif-
ficult.4 Subjective methods (such as the Ramsay Sedation Score [RSS]19 or the Riker 
Sedation-Agitation Scale [RSAS]20) and objective methods (as a physiologically based 
neurofunction monitor; Bispectral Index [BIS]) have been used in efforts to quantify 
the depth of sedation.21 The RSS is the most widely used observational assessment 
tool for evaluating sedation.17
Because no head-to-head studies have been reported between sedative agents for seda-
tion during NIV to date, we conducted this randomized, double-blind study to compare 
the sedative effects and the AE profile of dexmedetomidine versus midazolam for seda-
tion of ICU patients with decompensated COPD undergoing noninvasive mechanical 
ventilation. The hypothesis of our analysis was that dexmedetomidine may be better 
than midazolam for sedation during NIV in terms of sedative properties.
METHODS
The study was approved by the Local Committee on Human Subjects of the Kahra-
manmaras Sutcu Imam University Faculty of Medicine in 2006. Written informed 
consent was obtained from the relative who was directly responsible for each patient 
before study entry. Inclusion and exclusion criteria were determined by a study inves-
tigator who also managed coordination, sedation regimen, and when and how ventila-
tory support needed to be changed. Admitted patients with acute respiratory failure 
due to acute exacerbations of COPD in our ICU were assessed for participation in the 
study. Participants and study investigators were blind to allocation. Inclusion criteria 
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were age >18 years and patients with acute respiratory failure due to acute exacerbations 
of COPD in our ICU who had spontaneous breathing, but who were uncooperative, 
defined as 1 on the RSS and ≥1 on the RSAS.17,18 Patients with any of the following 
were excluded: requirement for immediate intubation (pH < 7.15); severe hypoten-
sion (mean arterial pressure <60 mm Hg); and acute cardiac ischemia or arrhythmias, 
sepsis, preexisting central nervous system dysfunction, hepatic failure (elevated >2× 
the maximum reference values of liver enzymes or history of hepatic disease), renal 
failure (defined by the RIFLE criteria; an acronym comprising Risk, Injury, and Failure; 
and Loss and End-stage kidney disease),22 gastrointestinal hemorrhage, and psychiatric 
illness (including use of antidepressant medication). Using a computer-generated ran-
domization schedule, patients were randomized to receive either dexmedetomidine 
(group D) or midazolam (group M) for sedation during NIV. Patients in group D 
received a loading dose of 1 μg/kg IV dexmedetomidine over 10 minutes followed by a 
maintenance infusion of 0.5 μg/kg/h dexmedetomidine. Those in group M received a 
loading dose of 0.05 mg/kg midazolam over 10 minutes followed by a maintenance 
infusion of 0.1 mg/kg/h midazolam.
The level of sedation was measured in all patients by the RSS, RSAS, and BIS 
(Table I).15,21,23 Outcomes were assessed by one of the study investigators (H.D.) 
who was blind to the allocation group. The infusion rate was adjusted to maintain 
a target sedation level of an RSS of 2 to 3, an RSAS score of 3 to 4, and a BIS level 
>85 by a study investigator (N.S.) who also determined whether ventilatory support 
needed to be changed. If the patient was inadequately sedated (RSS <2 or RSAS 
>4), the dexmedetomidine infusion was increased by 0.1 μg/kg/h and the midazo-
lam infusion was increased by 0.05 mg/kg/h. If, after 2 increases in the infusion rate 
of the sedative the patient was still not adequately sedated, he or she was switched 
to another sedative agent and withdrawn from the study. If the patient was overse-
dated (RSS >4 or RSAS <2), the infusion of drug was stopped until RSS of 2 to 3 
or RSAS score of 3 to 4 was achieved.
NIV was performed via facial mask using a ventilator (840 Series, Puritan-Bennett 
Corporation, Overland Park, Kansas) in bilevel positive airway pressure ventilation 
mode. NIV was started with fractional inspired oxygen of 50% and the level of ven-
tilatory support (pressure support) was increased 5 cm H2O in a stepwise fashion every 
5 to 15 minutes as clinically indicated.11 Optimal NIV was defined as the lowest pres-
sure level of NIV and the lowest fractional inspired oxygen that maintained oxygen 
saturation >90% or partial pressure of oxygen in arterial blood (PaO2) >60 mm Hg 
without deterioration of clinical parameters. The face mask was connected directly to 
the Y of the ventilator circuit to reduce dead space and then held in place by the fixa-
tion system to minimize air leaks. Initial ventilator settings were subsequently ad-
justed according to the patient’s tolerance, vital signs, and arterial blood gas (ABG) 
measurements. NIV failure was defined as the need for intubation or death causally 
related to NIV. Primary outcome measures were RSS, RSAS, and BIS. Secondary out-
come measures were heart rate (HR), blood pressure outcomes, and ABG at each in-
dividual time point. Parameters were measured at initiation of NIV and 1, 2, 4, 6, 8, 
12, and 24 hours after the loading dose was administered.
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Included patients did not receive any other sedatives/pain medications apart from 
the study medications. Also, all patients in both groups received similar medical care 
for the etiology of their respiratory insufficiency apart from the study medications 
(ie, bronchodilators, steroids, antibiotics, mucolytics).
The statistical analysis of data was performed with SPSS 11.0 (SPSS Inc., Chicago, 
Illinois). Data are expressed as mean (SD) or absolute values (age, height, and weight). 
The paired-sample t test was used for comparisons of repeated measurements within 
groups and the independent-sample t test for comparisons between groups. The non-
parametric data were evaluated with the χ2 test or Fisher exact test, when appropriate. 
P < 0.05 was considered statistically significant. Assuming an α level of 0.05 with a 
power of 0.80, a minimum of 17 patients were required in each group to detect a 
mean difference of 1 (1) for RSAS scores between the 2 groups. No adjustments for 
multiple comparisons were conducted.
Table I. Clinical sedation scales used for the study.
Ramsay Sedation Score19
  1. Awake; patient is anxious and agitated, or restless, or both
  2. Patient is cooperative, oriented, and tranquil
  3. Patient responds to commands only
  4.  Asleep; patient exhibits a brisk response to a light glabellar tap or loud auditory 
stimulus
  5.  Asleep; patient exhibits a sluggish response to a light glabellar tap or loud auditory 
stimulus
  6.  Patient does not respond to a light glabellar tap or loud auditory stimulus
Riker Sedation-Agitation Scale20
  1.  Unarousable: Minimal or no response to noxious stimuli; does not communicate or 
follow commands
  2.  Very sedated: Arouses to physical stimuli but does not communicate or follow 
commands; may move spontaneously
  3.  Sedated: Difficult to arouse; awakens to verbal stimuli or gentle shaking but drifts 
off again; follows simple commands
  4. Calm and cooperative: Calm, awakens easily, follows commands
  5.  Agitated: Anxious or mildly agitated, attempts to sit up, calms down to verbal 
instructions
  6.  Very agitated: Does not calm despite frequent verbal reminding of limits, requires 
physical restraints, biting endotracheal tube (ETT)
  7.  Dangerous agitation: Pulling at ETT, trying to remove catheters, climbing over bed 
rail, striking at staff, thrashing side-to-side
Bispectral Index21
  0–40: Deep hypnotic state
  41–60: Moderate hypnotic state
  61–70: Light hypnotic state
  71–100: Awake/light to moderate sedation
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RESULTS
Forty-five consecutive patients were assessed for inclusion; 5 patients were excluded 
(4 did not meet inclusion criteria and 1 refused to participate). Therefore, 40 patients 
were randomized (intent-to-treat patients) to receive dexmedetomidine (group D; 
n = 20) or midazolam (group M; n = 20), between June 2006 and March 2009. The 
patient disposition for this study is shown in Figure 1. The patients or family mem-
bers provided permission for the patient to participate. The clinical characteristics of 
the 40 patients are listed in Table II. There was no significant difference in terms of 
age or gender between the 2 groups.
Sedation
In both groups, RSS levels significantly increased and RSAS levels and BIS values 
were significantly decreased after the loading dose of sedative (P = 0.01). Between the 
groups, RSS levels were significantly lower at 2 hours after the loading dose was ad-
ministered in group D compared with group M. However, RSS levels were signifi-
Assessed for eligibility
(N = 45)
Randomization
Enrollment
Excluded (n = 5)
Not meeting inclusion 
criteria (4)
Refused to 
participate (1)
Allocation
Allocated to 
intervention (n = 20)
Received allocated 
intervention (20)
Allocated to 
intervention (n = 20)
Received allocated 
intervention (20)
Follow-up Discontinued 
intervention (n = 2)
Analysis Analyzed (n = 20)Analyzed (n = 20)
Figure 1.  Disposition of intensive care unit patients undergoing noninvasive mechanical 
ventilation who were equally randomized to receive dexmedetomidine or mid-
azolam for sedation.
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cantly lower beginning from the fourth hour in group D compared with group M 
(P < 0.05). RSAS levels were not significantly different between the 2 groups in the 
first 8 hours. However, RSAS levels were significantly higher at 8 hours after the load-
ing dose was administered in group D compared with group M (P < 0.01, Table III). 
BIS values were significantly higher in group D than in group M throughout the 
study period (P < 0.05). The number of times a change in infusion dose was needed 
was significantly lower in patients in group M (2 patients with 1 change each) than 
in group D (3 patients with 1 change, 1 patient with 2 changes, and 3 patients with 
3 changes each) (P < 0.01).
Gas Exchange
Respiratory rate decreased and pH level increased gradually after the loading dose 
in both groups (P < 0.05). Partial pressure of carbon dioxide in arterial blood de-
creased significantly in both groups (Figure 2, P < 0.05). There was no significant 
difference in PaO2 levels in both in-group comparisons and between-group compari-
sons (P > 0.05). Respiratory rates and gas exchange parameters in groups D and M 
were not significantly different.
Heart Rate and Blood Pressure Outcomes
Although baseline measurements of HR and arterial blood pressure between 
groups were not significantly different (P > 0.05), the patients in group D had signifi-
cantly lower HR levels compared with patients in group M throughout the study 
period. In group D, HR levels were significantly lower than those in group M during 
sedative infusion. Systolic arterial pressure and diastolic arterial pressure levels were 
lower for 2 hours after the loading dose was administered when compared with base-
line measurements. Systolic blood pressure and diastolic blood pressure were also 
significantly lower in group D during the first 2 hours than those in group M (P < 
0.05, Figure 3). However, there was no statistically significant difference in blood 
pressure levels 4 hours after the loading dose was administered. 
Table II.  Demographic data and Acute Physiology and Chronic Health Evaluation 
(APACHE II) scores of intensive care unit patients undergoing noninvasive 
ventilation who were randomized to receive dexmedetomidine or midazolam for 
sedation.* Data are median (range).
 Dexmedetomidine Midazolam 
Variable (n = 20) (n = 20)
Male/Female 9/11 10/10
Age, y 58 (28–80) 60 (30–81)
Body mass index, kg/m2 25.5 (20–30) 25.7 (22–30)
APACHE II  21.5 (17–26) 21.4 (18–28) 
* All patients received similar medical care (ie, bronchodilators, steroids, antibiotics, mucolytics) for the 
etiology of their respiratory insufficiency apart from the study medications.
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Adverse Effects
No patient experienced adverse cardiovascular effects related to the loading dose or 
infusion of the sedative agent. In group D, 2 patients required 1 adjustment in infu-
sion rate. In group M, 3 patients required 1 adjustment, 1 patient required 2, and 
3 patients required 3 dosing changes. Therefore, change of infusion rate was needed 
twice in group D and 14 times in group M (P < 0.01). Eight hours after the midazo-
lam infusion was initiated, oversedation (RSS >4 or RSAS <2) occurred in 1 patient 
in group M who required cessation of the infusion. Two patients in group M were still 
Table III.  Ramsay Sedation Score (RSS), Ricker Sedation-Agitation Scale (RSAS), and 
Bispectral Index (BIS) at various times during the course of sedation with dex-
medetomidine (group D, n = 20) or midazolam (group M, n = 20) in intensive 
care unit patients undergoing noninvasive ventilation. Values are presented as 
mean (SD) (range).
 Time (hour) Group D Group M P*
RSS Baseline 1.4 (0.5) (1–2) 1.2 (0.4) (1–2) 0.324
1 2.2 (0.5)† (2–3) 2.1 (0.7)† (1–3) 0.432
2 2.1 (0.3)† (2–3) 2.5 (0.7)† (1–4) 0.023
4 2.3 (0.5)† (2–3) 2.9 (0.8)† (1–4) 0.006
6 2.3 (0.5)† (2–3) 3.1 (0.7)† (2–4) <0.001
8 2.4 (0.7)† (2–4) 2.9 (0.8)† (2–5) 0.030
12 2.5 (0.5)† (2–4) 2.9 (0.7)† (2–4) 0.028
24 2.5 (0.5)† (2–3) 3.2 (0.6)† (2–4) <0.001
RSAS Baseline 5.2 (0.4) (5–6) 5.5 (0.7) (5–7) 0.052
1 3.8 (0.4)† (3–4) 4.3 (1.4)† (2–6) 0.168
2 3.7 (0.4)† (3–4) 3.9 (1.3)† (2–6) 0.632
4 3.8 (0.6)† (3–4) 3.9 (0.2)† (2–6) 0.673
6 3.7 (0.7)† (3–4) 3.6 (0.8)† (2–5) 0.879
8 3.8 (0.5)† (3–4) 2.9 (0.8)† (2–4) <0.001
12 3.8 (0.4)† (3–4) 3.1 (0.5)† (2–4) <0.001
24 3.8 (0.5)† (3–4) 3.2 (0.8)† (2–4) 0.002
BIS Baseline 96 (1.3) (94–99) 96 (1.1) (94–98) 0.522
1 94.6 (1.8)† (94–99) 91.3 (3.2)† (88–97) <0.001
2 94.5 (1.3)† (92–98) 91.5 (3.3)† (86–97) <0.001
4 93.3 (1.8)† (92–96) 88.2 (3.8)† (85–96) 0.001
6 92 (1.7)† (90–95) 88.7 (4.9)† (80–97) <0.001
8 92 (2.1)† (89–94) 88.8 (3.4)† (75–95) 0.012
12 92 (2.1)† (89–94) 88.8 (3.5)† (82–95) 0.001
24 90.9 (1.8)† (87–94) 86.8 (2.5)† (82–90) <0.001
*Between-group comparison.
†P < 0.05 versus baseline.
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Figure 3.  Hemodynamic parameters (heart rate [HR], systolic blood pressure [SBP], and 
diastolic blood pressure [DBP]) at baseline (time 0, before the loading dose of 
sedative was given) and after study drug administration in intensive care unit 
patients undergoing noninvasive ventilation who were randomized to receive a 
loading dose and infusion of dexmedetomidine (group D, n = 20) or midazolam 
(group M, n = 20) for sedation. *P < 0.05 for between-group comparisons; †P < 
0.05 for comparisons of repeated measurements within groups.
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agitated after 2 increases in the infusion rate of midazolam and were withdrawn from 
the study. No patient experienced NIV failure during the study period.
DISCUSSION
The present study compared the effectiveness of dexmedetomidine with midazolam for 
sedation during noninvasive mechanical ventilation in ICU patients in a double-blind, 
randomized, prospective fashion. Except for 2 patients, all patients satisfied the target 
criteria of a RSS score of ≥2 and a RSAS score of ≤5, experiencing adequate sedation 
without substantial changes in hemodynamics. We found 0.5 μg/kg/h of dexmedetomi-
dine to be not significantly different from a midazolam infusion of 0.1 mg/kg/h. Al-
though the level of sedation was not significantly different in the 2 groups, BIS values 
were higher in patients who were sedated with dexmedetomidine and fewer patients 
receiving dexmedetomidine required changes in the rate of infusion.
Appropriate levels of sedation are needed to prevent patient-ventilator asynchrony, 
thereby allowing for therapeutic mechanical ventilation. Dexmedetomidine is a useful 
sedative in ICU patients24: sedation is obtained when patients are undisturbed, but 
they can be easily aroused with minimal stimulation, allowing for the performance of 
frequent neurological examinations. In addition, it facilitates weaning from mechani-
cal ventilation in patients with asthma or COPD.25 Midazolam is a benzodiazepine 
that has a rapid onset and short duration of action with single doses, making it a 
preferred agent for treating acutely agitated patients.3 Accumulation and prolonged 
sedative effects of midazolam have been reported in critically ill patients who are 
obese, have low albumin levels, or renal failure.26 Its prolonged sedative effect in pa-
tients with renal insufficiency might be caused by the accumulation of an active me-
tabolite, α-hydroxymidazolam, or its conjugated salt.3,27 Paradoxical agitation has 
also been observed in ~1% of patients during light sedation and may be the result of 
drug-induced amnesia or disorientation.4 Indeed, in 2 patients of group M in the pres-
ent study, midazolam was ineffective. Otherwise, oversedation occurred in 1 patient 
8 hours after the midazolam infusion was begun. Sedation remained inadequate in 1 pa-
tient in group D and in 6 patients in group M, which necessitated an increase in infu-
sion dosing.
We compared 2 widely used sedative agents, dexmedetomidine and midazolam, in 
mechanically ventilated ICU patients. Dexmedetomidine infusion produced lower seda-
tion levels while appearing to improve agitation and anxiety. This might be explained, at 
least in part, by potential differences in the quality of sedation of the 2 drugs and possible 
accumulation of midazolam. Indeed, RSS levels were similar between both of the groups 
in the first 2 hours of the study. The patients sedated with dexmedetomidine had lower 
RSS levels at the second hour and higher RSAS levels 8 hours after administration of 
the loading dose. On the other hand, the BIS values were higher in the dexmedetomi-
dine group than those in patients receiving midazolam for the duration of the study.
Compared with group M, the lower HR during the study period in group D might 
be explained by the decreased sympathetic outflow and circulating levels of cate-
cholamines caused by dexmedetomidine.28 Midazolam is not known to have any sym-
patholytic effects.
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The limitations of the present study were that a small group was used and there 
was no control group. Larger, well-designed, randomized, controlled trials are needed 
to confirm the findings of this study.
CONCLUSIONS
In this pilot study, when comparing a loading dose and 24-hour infusion of dexmedeto-
midine or midazolam infusion for sedation in noninvasive mechanically ventilated ICU 
patients, both agents were found to be suitable and no significant difference in benefical 
effects on oxygenation and ventilation were observed. Patients treated with dexmedeto-
midine needed significantly fewer adjustments to maintain adequate sedation and coop-
eration with NIV. 
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